News InflaRx flatlines after skin disease drug flops in midstage ... Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug IFX-1 in a debilitating skin disease.
News Jazz pays $145m to resolve Xyrem antitrust disputes Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl